Skip to main content
Caplight Logo









iMediSync

iMediSync

Private
SeoulHealthcare & Life Scienceshttps://www.imedisync.com/

Last Round

Series C

Nov 30, 2021

Total Funding Raised

$15.84M

Company Overview

iMediSync is a digital health company that provides an AI-based platform for mental healthcare, including EEG/HRV measurement devices and analysis software.

Sector

Healthcare & Life Sciences

Verticals

Medical Devices, Mental Health, Medical AI, Healthcare Analytics

Business Model

B2B

Customer Profile

Hardware + Subscription, Hardware Sales, Subscription SaaS, Usage-Based SaaS, Government Contracts

AI Layer

Application

Keywords

AI brainwave analysisdigital mental healthwireless EEGquantitative EEGQEEGneurotechdry EEG headsetneurological biomarkersbrain mappingmental health techHRV analysisMCI screeningneurofeedbackmedical devicebrain computer interfacedementia screeningFDA clearance

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

iMediSync Comparables

Compare iMediSync with similar companies based on industry and business-model similarity.

iMediSync comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
Zeto, Inc.
87%
Firefly Neuroscience, Inc.
79%
Advanced Brain Monitoring Inc.
77%

iMediSync Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
Series CNov 30, 2021
GrantJul 25, 2020
Series BApr 7, 2020
Series AJun 1, 2018

iMediSync Investors

Notable investors and investment history

iMediSync investors
InvestorRounds
A VenturesSeries B
NHN InvestmentSeries A
Ministry of Trade, Industry and EnergyGrant
Korea Development BankSeries B
Government of South KoreaGrant, Accelerator

Market signals

Structured signals derived from secondary market and firmographic data.

  • Jul 17, 2025

    Grew 33% QoQ from 9 to 12 employees.

  • Nov 30, 2021

    Raised $6.4M in Series C funding.

iMediSync Filings

Explore SEC and related filing metadata, where available.

iMediSync filings preview — column headings only; records require access
TypeDateAmount OfferedAmount SoldFilingPagesDownload

Filing documents are not displayed on this public page. Request access to learn about available coverage.

Request access

Frequently Asked Questions

Common questions about iMediSync's valuation, stock price, and market status.

Is iMediSync a public or private company?

iMediSync is a private company.

What is the current stock price of iMediSync?

iMediSync is a private company with no public stock price. No recent secondary market data is available.

How much is iMediSync worth (valuation)?

Valuation information for iMediSync is not publicly available.

Can I buy iMediSync stock?

iMediSync shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors. Visit https://www.caplight.com to learn more.

When was iMediSync's last funding round?

iMediSync's most recent funding round was Series C on November 30, 2021.

Who are the main investors in iMediSync?

Key investors in iMediSync include Korea Development Bank.

Will iMediSync IPO soon?

No public IPO plans have been announced for iMediSync.

How can I track iMediSync secondary market activity?

Caplight tracks bids, offers, and trades for private companies. Visit https://www.caplight.com to monitor iMediSync's secondary market activity and sign up for updates.

Firmographic Details

HeadquartersSeoul
Employee Range12
Year Founded2012
Last FundingNov 30, 2021

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.

See something wrong or outdated?